Mon Sep 09 16:10:16 UTC 2024: ## ArriVent BioPharma’s Firmonertinib Shows Promising Results in Lung Cancer Trial

**NEWTOWN SQUARE, PA -** ArriVent BioPharma, Inc. (NASDAQ: AVBP) has announced positive interim results from a Phase 1b trial of firmonertinib, its oral, once-daily medication, for patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). The data, presented at the World Conference on Lung Cancer, suggests firmonertinib could be a highly effective first-line treatment for this patient group, including those with brain metastases.

The trial demonstrated an 81.8% overall response rate (ORR) at the 240 mg dose, with 90.9% of patients with confirmed responses remaining on study. Notably, the drug showed a 46.2% confirmed ORR in patients with central nervous system (CNS) metastases, a challenging aspect of advanced NSCLC.

Firmonertinib has shown broad activity across EGFR mutations and good tolerability with the most common side effects being diarrhea, rash, and dry skin. Importantly, no treatment discontinuations due to side effects have been observed.

These promising results highlight firmonertinib’s potential as a chemotherapy-free treatment option, particularly for patients with CNS disease. This is especially significant as current treatments have limited effectiveness against uncommon mutations like PACC, which represent a significant portion of NSCLC EGFR mutations.

**Analyst Reactions and Investment Outlook**

The positive trial results have led to a surge in investor interest in ArriVent BioPharma. Analyst firm H.C. Wainwright has raised its price target for AVBP shares to $30.00, while Oppenheimer initiated coverage with an Outperform rating and a $35.00 price target.

However, while ArriVent’s financial position is strong with over $317 million in cash, investors should note that the company is not expected to be profitable this year. InvestingPro, a financial analysis platform, has also flagged potential concerns about the recent price increase being overbought.

**Moving Forward**

ArriVent BioPharma is currently working on further development of firmonertinib for NSCLC patients with specific EGFR PACC mutations. The company is also exploring a multi-target, multivalent antibody-drug conjugate and collaborating with Jiangsu Alphamab Biopharmaceuticals to develop novel antibody-drug conjugates for cancer treatment.

The company’s focus on addressing unmet medical needs in the cancer space and its promising clinical trial results have positioned ArriVent BioPharma as a key player in the lung cancer treatment landscape. Investors will be closely watching the company’s progress as it moves towards potential FDA approval for firmonertinib.

Read More